Results 81 to 90 of about 35,110 (216)

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. [PDF]

, 2015
Epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN). In addition to EGFR, other ErbB family members are expressed and activated in SCCHN. Afatinib is an ErbB family blocker
Baum, Anke, Cohen, Ezra EW, Grushko, Tatyana A, Hardeman, Ashley, Liu, Jing, Olopade, Olufunmilayo I, Solca, Flavio, Soneru, Christian, Young, Natalie R   +8 more
core   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Scientific Reports, 2019
Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospectively
Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard   +20 more
doaj   +1 more source

Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma

Journal of Translational Medicine, 2018
Background The functions of the protein expressed in the nucleus and cytoplasm were different or opposite. The previous study found that oncogene Klf4 played a role of tumor suppressor in the nasopharyngeal cytoplasm.
Xiqing Li, Zunlan Zhao, Shijiang Yi, Lei Ma, Ming Li, Mingyue Liu, Yaping Zhang, Guangzhi Liu   +7 more
doaj   +1 more source

Анализ и способы повышения конкурентоспсособности предприятия [PDF]

, 2011
Dysregulation of growth factor receptors such as the epidermal growth factor receptor (EGFR) and of its truncated form EGFRvIII is frequently found in human tumors.
Barth, S., Dreier, A., Goswami, A., Weis, J.   +3 more
core   +1 more source

Data Supplement from AXL Mediates Resistance to Cetuximab Therapy

, 2023
<p>Supplemental Materials and Methods. Supplemental materials and methods including qPCR primers and in vivo PDX establishment and characterization.</p>
Deric L. Wheeler, Randall J. Kimple, Ravi Salgia, Parkash S. Gill, Mahmoud Toulany, Neha Luthar, Cara M. Braverman, Kelsey L. Corrigan, Andrew P. Stein, Mari Iida, Toni M. Brand   +10 more
openaire   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab [PDF]

European Journal of Cancer, 2016
Abstract Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non–small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do not respond to cetuximab.
Iida, M., Bahrar, H., Brand, T.M., Pearson, H.E., Coan, J.P., Orbuch, R.A., Flanigan, B.G., Swick, A.D., Prabakaran, P.J., Lantto, J., Horak, I.D., Kragh, M., Salgia, R., Kimple, R.J., Wheeler, D.L.   +14 more
openaire   +3 more sources

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

Advanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen, Yi‐Fan Zhou, Xuan Qi, Ya‐Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi‐Zhou Jiang, Zhi‐Ming Shao   +8 more
wiley   +1 more source

Rap2B-mediated reprogramming of the PI3K/AKT signaling axis drives resistance to cetuximab-targeted therapy in colorectal carcinoma

Biological Procedures Online
Background Targeted therapy resistance represents a significant clinical challenge in cancer treatment. Rap2B, a member of the Ras superfamily of small GTPases, is frequently overexpressed in various cancers and has been implicated in promoting tumor ...
Shanshan Zhang, Ying Wei, Tingting Liu, Chenhao Sun, Xiuzhen Ge, Yang Ni, Xiaonan Tang, Mridul Roy, Tingmin Chang, Xiaohong Kang   +9 more
doaj   +1 more source